Connecticut Wealth Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,764 shares of the The company’s stock after buying an additional 1,200 shares during the quarter. Connecticut Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,412,000 at the end of the most recent quarter.

→ Is This The End of Capitalism? (From Porter & Company)

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Morton Brown Family Wealth LLC boosted its stake in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC 1 7 now owns of the company’s stock worth $32,000 after acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at $39,000. John First Bank & Trust increased in its stake by 69.6% in the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after purchasing an additional 156 shares in the last quarter. Heritage Wealth Management LLC acquired a new stake in Johnson & Johnson during the 2nd quarter about $84,000. Finally, Timber Creek Capital Management LLC lifted its stake in Johnson & Johnson by 225.0% during the third quarter. Timber Creek Capital Management t LLC now owns 650 shares of the company’s stock valued at $106,000 after buying an additional 450 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. com Following the the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news sholdley, EVP A 73,323 shares of the company’s stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the transaction, the executive vice in 83 president now direct 4 the company, valued at approximately $7,336,927.11. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jose ph J. Wolk sold 14,781 shares of the firm’s stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the sale, the chief financial now owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 233,611 shares of company stock worth $40,960,735. 0.35% by the insiders is owned

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on JNJ shares. Raymond James reduced their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Sanford C. Bernstein dropped their price target on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday , October 19th. Bank of America decreased their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Finally, StockNews.com began coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $181.75.

Johnson & Johnson Stock Up 0.7 %

Johnson & Johnson stock opened at $169.51 on Thursday. The company has a market capitalization of $443.18 billion, a P/E ratio of 23.61, a P/E/G ratio of 3.10 and a beta of 0.56. Johnson & Johnson has a 1- year low of $155.72 and a 1-year high of $186.69. The firm’s fifty day simple moving average is $175.90 and its 200-day simple moving average is $171.04. The company has a current ratio of 1.43, a quick ratio of a debt of 1.18 and -to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson hadurn a return John on equity of 35.37% and a net margin of 19.95%. The company had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same quarter in the previous year, the firm earned $2.13 earnings per share. The business’s quarterly revenue was down 4.4% compared to the same quarter last year. Sell-side analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield.67% of 2 The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story [email protected].

Before you consider Johnson & Johnson, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.

While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here